## Peter de Blank

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/776819/publications.pdf

Version: 2024-02-01

430874 315739 1,709 48 18 38 citations h-index g-index papers 49 49 49 2926 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007–2011. Neuro-Oncology, 2015, 16, x1-x36.	1.2	414
2	American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro-Oncology, 2016, 18, i1-i50.	1.2	212
3	Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e305-e316.	10.7	115
4	The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010. Neuro-Oncology, 2014, 16, 1392-1399.	1,2	100
5	Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. Journal of Neuro-Ophthalmology, 2017, 37, S23-S32.	0.8	99
6	Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. Cancer, 2015, 121, 102-112.	4.1	98
7	Management of pediatric low-grade glioma. Current Opinion in Pediatrics, 2019, 31, 21-27.	2.0	87
8	Anti–N-methyl-D-aspartate Receptor-Mediated Encephalitis in Infants and Toddlers: Case Report and Review of the Literature. Pediatric Neurology, 2014, 50, 181-184.	2.1	66
9	Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. Journal of Neuro-Oncology, 2017, 135, 433-441.	2.9	62
10	Trends in Clostridium difficile Infection and Risk Factors for Hospital Acquisition of Clostridium difficile among Children with Cancer. Journal of Pediatrics, 2013, 163, 699-705.e1.	1.8	61
11	Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1. Neuro-Oncology, 2013, 15, 1088-1095.	1.2	42
12	Choroid plexus tumors in adult and pediatric populations: the Cleveland Clinic and University Hospitals experience. Journal of Neuro-Oncology, 2017, 132, 427-432.	2.9	39
13	Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009. Cancer Medicine, 2015, 4, 608-619.	2.8	36
14	Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brain Tumors. Pediatric Neurosurgery, 2019, 54, 310-318.	0.7	32
15	Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1. Journal of Clinical Oncology, 2019, 37, 3050-3058.	1.6	27
16	A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Journal of Neuro-Oncology, 2020, 149, 511-522.	2.9	27
17	Molecular markers and targeted therapy in pediatric low-grade glioma. Journal of Neuro-Oncology, 2020, 150, 5-15.	2.9	23
18	Impact of vision loss among survivors of childhood central nervous system astroglial tumors. Cancer, 2016, 122, 730-739.	4.1	21

#	Article	IF	CITATIONS
19	Variation in Risk of Hospital-Onset Clostridium difficile Infection Across Â-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 329-335.	1.3	18
20	Neurocognitive outcomes in neurofibromatosis clinical trials. Neurology, 2016, 87, S21-30.	1.1	16
21	Systemic Chemotherapy and White Matter Integrity in Tracts Associated with Cognition Among Children With Neurofibromatosis Type 1. Pediatric Blood and Cancer, 2016, 63, 818-824.	1.5	14
22	A Rare Case of Ectopic Recurrence of a Craniopharyngioma Diagnosed 17 Years After Initial Presentation. Journal of Pediatric Hematology/Oncology, 2011, 33, 392-397.	0.6	13
23	Validation of an automated tractography method for the optic radiations as a biomarker of visual acuity in neurofibromatosis-associated optic pathway glioma. Experimental Neurology, 2018, 299, 308-316.	4.1	13
24	Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas. Acta Neuropathologica Communications, 2020, 8, 182.	5.2	11
25	Childhood Cancer and Brain Tumor Late Effects: Relationships with Family Burden and Survivor Psychological Outcomes. Journal of Clinical Psychology in Medical Settings, 2017, 24, 279-288.	1.4	9
26	Tumor Response Assessment in Diffuse Intrinsic Pontine Glioma: Comparison of Semiautomated Volumetric, Semiautomated Linear, and Manual Linear Tumor Measurement Strategies. American Journal of Neuroradiology, 2020, 41, 866-873.	2.4	7
27	Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study. Genetics in Medicine, 2020, 22, 1794-1802.	2.4	7
28	Effects of genetic background on cardiovascular anomalies in the Ts16 mouse. Developmental Dynamics, 2005, 232, 131-139.	1.8	5
29	Recommendations for Measurement of Attention Outcomes in Preschoolers With Neurofibromatosis. Neurology, 2021, 97, S81-S90.	1.1	4
30	Effect of age and neurofibromatosis type $1$ status on white matter integrity in the optic radiations. Neuro-Oncology Advances, 2020, 2, i150-i158.	0.7	3
31	Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1. Neurology, 2021, 97, S73-S80.	1.1	3
32	Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor. Journal of Pediatric Hematology/Oncology, 2021, 43, e550-e553.	0.6	3
33	fdg-pet in Two Cases of Neurofibromatosis Type 1 and Atypical Malignancies. Current Oncology, 2014, 21, 345-348.	2.2	2
34	Overcoming barriers to establishing autopsy procurement programs in pediatric patients with central nervous system tumors: a call to develop regional centers. Journal of Neuro-Oncology, 2021, 152, 107-114.	2.9	2
35	Neurofibromatosis type $1$ and risk of late outcomes after a primary tumor: A report from the Childhood Cancer Survivor Study Journal of Clinical Oncology, 2018, 36, 10563-10563.	1.6	1
36	Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry. Neuro-Oncology, 2022, , .	1.2	1

#	Article	IF	CITATIONS
37	Window-of-opportunity study of ONC201 in pediatric patients with diffuse intrinsic pontine glioma (DIPG) and thalamic glioma Journal of Clinical Oncology, 2022, 40, TPS2082-TPS2082.	1.6	1
38	Late mortality and morbidity among adult survivors of childhood glioma treated over three decades: A report from the Childhood Cancer Survivor Study Journal of Clinical Oncology, 2022, 40, 10007-10007.	1.6	1
39	Advanced Magnetic Resonance Imaging in Optic Pathway Gliomas. Journal of Pediatric Neuroradiology, 2016, 04, 132-144.	0.1	0
40	GENE-22. MOLECULAR ALTERATIONS AND USE OF TARGETED THERAPY IN 160 PEDIATRIC PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS. Neuro-Oncology, 2019, 21, ii86-ii86.	1.2	0
41	LGG-10. AN UNUSUAL PRESENTATION OF BILATERAL OPTIC NERVE GLIOMA IN CROUZON SYNDROME. Neuro-Oncology, 2021, 23, i33-i33.	1.2	0
42	Approach to patients with the neoplasms associated with neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis., 2021,, 210-228.		0
43	NIMG-11. VOLUMETRIC ENDPOINTS IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): COMPARISON TO CROSS-SECTIONAL MEASURES AND CORRELATION WITH OUTCOMES. Neuro-Oncology, 2021, 23, vi129-vi130.	1.2	0
44	CTNI-36. SAFETY OF ONC201 ADMINISTERED TWO CONSECUTIVE DAYS PER WEEK IN PEDIATRIC H3 K27M-MUTANT GLIOMA PATIENTS. Neuro-Oncology, 2021, 23, vi67-vi67.	1.2	0
45	LGG-24. Neurocognitive impairment and functional independence in adult survivors of childhood glioma: A report from the Childhood Cancer Survivor Study (CCSS). Neuro-Oncology, 2022, 24, i93-i93.	1.2	0
46	EPCT-05. Phase Ib study of unesbulin (PTC596) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG): A report from the COllaborative Network for NEuro-Oncology Clinical Trials (CONNECT). Neuro-Oncology, 2022, 24, i36-i36.	1.2	0
47	EPCT-06. Phase I study of ribociclib and everolimus post-radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG): Updated report from the COllaborative Network for NEuro-Oncology Clinical Trials (CONNECT). Neuro-Oncology, 2022, 24, i36-i37.	1.2	0
48	NFB-04. Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on PBTC-029B. Neuro-Oncology, 2022, 24, i128-i129.	1.2	0